ScripRecently launched Kailera Therapeutics believes it has a highly effective, differentiated obesity candidate on its hands after China-based partner Hengrui unveiled positive Phase III data for its dual
ScripA new wave of mid-sized biopharma companies is being created in China, driven on by in-house R&D and big pharma licensing deals. That is the picture emerging from data captured by Evaluate Pharma
ScripThe number of competitive drug candidates transferring from Chinese research and development pipelines to US-based biopharmaceutical company portfolios has grown significantly during the first half of
ScripAmong Chinese developers of weight management medicines presenting at the June 20–23 American Diabetes Association (ADA) congress, Sciwind Biosciences and Laekna Therapeutics appeared to be the stand-